Abstract: The present invention relates to a method for detecting protein-protein interactions by assessing interaction in a eukaryotic cell of a first fusion protein that specifically binds to GFP and accumulates at distinct sites in the nucleus of the cell or interacts with structures accumulated at distinct sites in the nucleus of the cell; a second fusion protein comprising GFP and a bait (poly)peptide; and a third fusion protein comprising a fluorescent (poly)peptide having an excitation and/or emission wavelength that differs from that of GFP and a prey (poly)peptide. The emissions from the fluorescent parts of the fusion proteins are observed. Co-localization of the emissions from both fluorescent fusion proteins indicates interaction of the bait and the prey (poly)peptide. Methods for identifying a compound modulating the interaction of two (poly)peptides and methods of determining the relative strength of the interaction of two proteins with a third protein.

Abstract: Replication-defective lentiviral vectors are described. Using this vector, methods of directing evolution of a target polynucleotide of interest for obtaining variants of the target polynucleotide, methods to generate genetic variability by preparing a cell library, and methods to isolate and/or screen variants of a polynucleotide or variants of a protein able to impact the phenotype of a cell or to confer a desired phenotype to target cells and to identify theses polynucleotide variants or protein variants responsible for this phenotype are described.

Abstract: This invention relates to the purification of nucleic acid conjugates, for example for use in DNA encoded chemical libraries. Reaction members that comprise nucleic acid conjugate reaction products and nucleic acid or nucleic acid conjugate reactants comprising a first reactive group are contacted with a capping molecule comprising a capture group. The capping molecule reacts with the first reactive group to form a covalent bond, thereby attaching the capture group to nucleic acid or nucleic acid conjugate reactants in reaction members. The nucleic acid or nucleic acid conjugate reactants are then removed from the reaction members using a binding member that binds the capture group, thereby producing a purified population of nucleic acid conjugate products. Methods of producing purified populations of nucleic acid conjugate products and nucleic acid chemical libraries are provided along with chemical libraries and kits.

Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.

Abstract: Provided is a novel useful microRNA having improved anti-tumour activity, obtained by introducing a variation in a microRNA which is present in-vivo and which exhibits an anti-tumour effect. This microRNA containing a base sequence (SEQ ID NO: 1) obtained by varying a predetermined region of the base sequence of miR-29b is able to exhibit a particularly outstanding anti-tumour effect.

Abstract: Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a miRNA-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition. The kit includes a vial containing an miRNA-762 inhibitor and a device for use in a surgery creating a risk of fibrosis and/or collagen deposition. The composition includes a pharmaceutical composition comprising a miRNA-762 inhibitor and a second agent selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitors, an angiotensin receptor blocker (ARB), another antihypertensive agent, a steroid, and combinations thereof.

Abstract: Methods are disclosed for treating multiple sclerosis comprising administering an agent that reduces expression and/or activity of Allograft inflammatory factor-1 (Aif-1) in a subject and for screening for such agents.

Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes.

Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

Abstract: The invention provides a binding-induced DNA nanomachine that can be activated by proteins and nucleic acids. This new type of nanomachine hamesses specific target binding to trigger assembly of separate DNA components that are otherwise unable to spontaneously assemble. Three-dimensional DNA tracks of high density are constructed on gold nanoparticles functionalized with hundreds of single-stranded oligonucleotides and tens of an affinity ligand. A DNA swing arm, free in solution, can be linked to a second affinity ligand. Binding of a target molecule to the two ligands brings the swing arm to AuNP and initiates autonomous, stepwise movement of the swing arm around the AuNP surface. The movement of the swing arm generates hundreds of oligonucleotides in response to a single binding event. The new nanomachines have several unique and advantageous features over DNA nanomachines that rely on DNA self-assembly.

Abstract: An object of the present invention is to develop and provide a method for efficiently producing a nucleic acid aptamer, particularly, a DNA aptamer, having higher specificity and binding activity against a target substance than those of nucleic acid aptamers obtained by conventional methods. The present invention provides a transcribable or replicable nucleic acid aptamer comprising a natural nucleotide and a non-natural nucleotide having an artificial base-pairable artificial base. The present invention also provides a method for sequencing a non-natural nucleotide-containing single-stranded nucleic acid molecule selected from a single-stranded nucleic acid library.

Abstract: The present invention relates to compositions and methods for delivery of siRNA to specific cells or tissue. More particularly, the present invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer.

Abstract: CRISPR/CAS-related compositions and methods for treatment of HSV-1 are disclosed.

Abstract: The purpose of the present invention is to provide a colorectal cancer drug that uses microRNA exhibiting outstanding effectiveness in colorectal cancer patients, particularly colorectal cancer patients having a mutated KRAS gene. miR4689 and/or miR4685-3p can suppress the growth of colorectal cancer cells, particularly colorectal cancer cells having a mutated KRAS gene, and thus exhibit an effective antitumor effect.

Abstract: Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. In some aspects, the methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. Methods of treatment for breast cancer and methods of identifying patients having cancer that are likely to benefit from treatment with a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor are also provided.

Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.

Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).

Abstract: The present invention relates to an antagonist or modulator of SLC38A9 for use in treating a disease associated with mTORC1 activation, like a proliferative disease (e.g. a cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder. Exemplary diseases to be treated are cancerous diseases like lung cancer, breast cancer, bladder cancer, pancreatic cancer, ovarian cancer, colon carcinoma, leukemia, lymphoma, melanoma, esophageal cancer and stomach cancer; or metabolic disorders like overweight (pre-obesity), obesity or diabetes. Also provided herein are methods for treating, preventing or ameliorating such diseases comprising the administration of an antagonist of SLC38A9 to a subject in need of such a treatment, prevention or amelioration.

Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 3-hydroxyisobutyrate or MAA. Also provided herein are methods for using such an organism to produce 3-hydroxyisobutyrate or MAA.

Abstract: Disclosed is a method for suppressing the growth of a target cell, which is not limited in the type of a target cell and the type of a protein to be expressed in the target cell and needs not any preparatory experiment for determining a codon to be contained in a protein to be expressed in a target cell. Specifically disclosed is a method for suppressing the growth of a target cell, which comprises the steps of: incorporating DNA containing a region encoding a protein into the target cell, and allowing a protein encoded by the DNA to be expressed in the target cell into which the DNA has been incorporated. The region contained in the DNA comprises a tri-nucleotide sequence. The tri-nucleotide sequence is selected from codons that define at least some amino acid species constituting the protein, and is complementary to at least some codons that are used in the target cell at a frequency of 0.2 or less.

Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.

Abstract: Provided is a transgenic plant production method for producing a genetically modified plant. The method is capable of efficient short term gene transfer, of introducing a target gene while retaining the useful traits of a plant undergoing gene transfer, and of efficient redifferentiation. The transgenic plant production method for producing a genetically modified plant includes a culture step of culturing a tissue fragment derived from a target plant to obtain a cultured tissue fragment, a transformation step of transforming, with a gene construct, the cultured tissue fragment obtained in the culture step, and a regeneration step of regenerating a plant from the tissue fragment transformed in the transformation step.

Abstract: The present invention provides cell lines for high efficiency genome editing using cas/CRISPR systems, methods of generating such cells lines, and methods of generating mutations in the genome of an organism using such cell lines.

Abstract: This disclosure concerns compositions and methods for targeting peptides, polypeptides, and proteins to plastids of plastid-containing cells. In some embodiments, the disclosure concerns chloroplast transit peptides that may direct a polypeptide to a plastid, and nucleic acid molecules encoding the same. In some embodiments, the disclosure concerns methods for producing a transgenic plant material (e.g., a transgenic plant) comprising a chloroplast transit peptide, as well as plant materials produced by such methods, and plant commodity products produced therefrom.

Abstract: The invention relates to a method for increasing the frequency of meiotic recombination in plants, by inhibiting the RECQ4 or TOP3A protein, especially by mutagenesis or extinction of the RECQ4 or TOP3A gene coding for said protein. The invention can be used especially in the field of plant breeding and genetic mapping.

Abstract: An isolated nucleic acid molecule is provided comprising a nucleotide sequence which encodes a glutamine:fructose-6-phosphate amidotransferase from E. coli which is particularly suitable for expression in cotton plant cells. The invention also relates to plant cells or plants, in particular to cotton plant cells or cotton plants which produce an increased amount of positively charged polysaccharides in their cell walls. Furthermore methods and means are provided to increase the content of positively charged polysaccharides in the cell walls of cotton cells, in particular in cotton fibers. Fibers obtained from such cotton plants have an altered chemical reactivity which can be used to attach reactive dyes or other textile finish reagents to these fibers.

Abstract: Provided are isolated polynucleotides which are at least 80% homologous to SEQ ID NO: 320, 1-319, 321-473, 836-1652, 1654-3221, 3225-3241, 3243-3630, 3632-4176 or 4177; and isolated polypeptides which are at least 80% homologous to SEQ ID NO: 760, 474-759, 761-770, 772-835 and 4178-4195, 4197-4213, 4215-4216, 4218-5334, 5336-5522, 5524-5754, 5756-6215, 6217, 6220-6223, 6230, 6232, 6235-6607, 6609-6614, 6620-7129 or 7130, nucleic acid constructs comprising the isolated polynucleotides, transgenic plants expressing same and methods of using same for increasing abiotic stress tolerance, yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, and/or nitrogen use efficiency of a plant.

Abstract: The present invention relates to transgenic citrus trees resistant to Huanglongbing disease (HLB) through overexpression of AtNPR1 either in the phloem tissues (where HLB resides) via utilization of a phloem specific Arabidopsis sucrose-proton symporter 2 (AtSUC2) promoter or a constitutive CaMV 35S promoter for HLB resistance. Evaluation of these transgenic plants demonstrates that overexpressing the AtNPR1 can result in effective HLB resistance in citrus.

Abstract: The present disclosure is in the field of plant breeding and disease resistance. The disclosure provides methods for breeding corn plants having downy mildew (DM) resistance using marker-assisted selection. The disclosure further provides corn germplasm resistant to DM. The disclosure also provides markers associated with DM resistance loci for introgressing these loci into elite germplasm in a breeding program, thus producing novel DM resistant germplasm.

Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.

Abstract: Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Certain of the vectors are able to cross tightly controlled biological junctions, such as the blood-brain barrier, which open up additional novel uses and target organs for the vectors, providing for additional methods of gene therapy and drug delivery.

Abstract: Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.

Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

Abstract: This invention encompasses methods of making 1-propanol. In some embodiments the methods comprise providing a cultured bacterial biofilm; culturing the bacterial biofilm under conditions suitable for production of 1-propanol; and collecting 1-propanol produced by the biofilm culture. In some embodiments the methods comprise providing a bacterial culture comprising bacteria and culture media, wherein the culture media comprises a concentration of threonine higher than that present in LB; maintaining the bacterial culture under conditions suitable for production of 1-propanol; and collecting 1-propanol produced by the culture. This invention also encompasses bacterial culture systems. In some embodiments the bacterial culture systems comprise a bacterial biofilm comprising bacteria growing on an artificial solid substrate; culture media; 1-propanol in liquid and/or gas form; and a collection device configured to collect 1-propanol produced by the culture.

Abstract: Provided are methods, systems and apparatuses to the energy efficient and selective extraction of biomolecules, e.g., small organic compounds, e.g., one or more C3-C9 alcohols, one or more C3-C5 carboxylic acids, and mixtures thereof, from an aqueous solution, particularly aqueous solutions containing the alcohol in dilute or low concentrations, for example, fermentation broths.

Abstract: The present invention relates to a method for preparing an adipate ester or thioester. The invention further relates to a method for preparing adipic acid from said ester or thioester. Further the invention provides a number of methods for preparing an intermediate for said ester or thioester. Further the invention relates to a method for preparing 6-amino caproic acid (6-ACA), a method for preparing 5-formyl valeric acid (5-FVA), and a method for preparing caprolactam. Further, the invention relates to a host cell for use in a method according to the invention.

Abstract: A method to prepare functional polyester polyols by using micro-reaction device, wherein mixing ?-caprolactone/?-valerolactone monomer with mercapto alcohol evenly with appropriate organic solution under moistureless conditions, and continuously transferring the prepared mixing solution into a micro-reaction device supported with an immobilized enzyme for polymerization to synthetize a poly (?-caprolactone/?-valerolactone). Compared with the prior art, the present invention achieves a continuous production by using immobilized lipase Novozyme435 as a catalyst.

Abstract: The invention is directed to a method for recovering a lipid or hydrocarbon from a fermentation mixture, comprising the steps of—providing a fermentation mixture wherein the lipid or hydrocarbon is produced by microbial fermentation in a fermentation vessel, which mixture comprises an aqueous phase and a liquid product phase, wherein the liquid product phase comprises the lipid or hydrocarbon; and—feeding at least part of the aqueous phase and part of the liquid product phase to a second vessel, thereby forming a second mixture; and—promoting phase-separation of the aqueous and product phase by injecting a gas into the second mixture, thereby separating the product phase from the aqueous phase; and—collecting the product phase comprising the lipid or hydrocarbon.

Abstract: The purpose of the present invention is to effectively accumulate triacylglycerol in algae cells, the present invention providing a method for introducing a triacylglycerol synthetase gene, a phosphorus starvation-inducible promoter, and a 3? untranslated region into algae.

Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids.

Abstract: A transaminase and a use thereof are provided. The transaminase has the amino acid sequences as shown in SEQ ID NO: 2 or 4, or has at least 80% identity to the amino acid sequences as shown in SEQ ID NO: 2 or 4, or has amino acid sequences which are obtained by the substitution, deletion or addition of one or more amino acids and have an the activity of an omega-transaminase with high stereoselective R-configuration catalytic activity, wherein the high stereoselective refers to the content of one of the stereoisomers being at least about 1.1 times that of the other.

Abstract: A method for producing an L-amino acid is provided. An L-amino acid is produced by culturing a bacterium belonging to the family Enterobacteriaceae and having an L-amino acid-producing ability, wherein the bacterium has been modified so that the activity of aconitase is increased, or the activities of aconitase and acetaldehyde dehydrogenase are increased, in a medium, and collecting the L-amino acid from the medium or cells of the bacterium.

Abstract: The present invention provides methods for the production of cysteine or derivates thereof by culturing a microorganism having reduced activity of endogenous phosphoserine phosphatase. The O-phosphoserine produced by such an organism can then be reacted with a sulfide in the presence of a sulfydrylase or a microorganism expressing a sulfhydrylase to produce cysteine or a derivative thereof. Microorganisms having the properties noted above are also provided herein.

Abstract: The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.

Abstract: The present invention describes a process for in situ generation of stable GOS in different dairy products by the use of a transgalactosylating ?-galactosidase.

Abstract: The process for the hydrolysis of ligno-cellulosic biomass comprises the steps of A) Contacting a ligno-cellulosic feedstock, the feedstock comprised of biomass having a dry content and water with at least a portion of a solvent, the solvent comprised of water soluble hydrolyzed species; wherein at least some of the water soluble hydrolyzed species are the same as the water soluble hydrolyzed species obtainable from the hydrolysis of the biomass in the feedstock; B) maintaining the contact between the feedstock of the feedstock stream and the solvent at a temperature in the range of 20° C. to 200° C. for a time in the range of 5 minutes to 72 hours to create a hydrolyzed product from the biomass in the feedstock.

Abstract: The present invention relates to the field of biotechnology engineering. It provides a method of constructing a recombinant Bacillus subtilis that can produce specific-molecular-weight hyaluronic acids. By integranted expression of hasA from Streptococcus zooepidemicus and overexpression of genes of HA synthetic pathway, tuaD, glmU and glmS, high yield HA production was achieved in the recombinant strain. Additionally, introduction and functional expression of the leech hyaluronidase in the recombinant strain substantially increased the yield of HA to 19.38 g·L?1. Moreover, HAs with a broad range of molecular weights (103 Da to 106 MDa) were efficiently produced by controlling the expression level of hyaluronidase using RBS mutants with different translational strengths. The method of the present invention can be used to produce low molecular weight HAs at large scale in industrial applications.

Abstract: Provided is a composition for producing astringin among metabolites of polydatin, wherein the astringin may be mass-produced by oxidizing the polydatin using a CYP102A1 chimera and mutants thereof as a catalyst, the CYP102A1 chimera being produced by fusing a reductase domain of a wild-type CYP102A1 which is a bacterial cytochrome P450 enzyme, with a heme domain of a CYP102A1 mutant.